^
    Back
    Association details:
    Biomarker:CXCL8 elevation
    Cancer:Hepatocellular Cancer
    Drug:Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    Liver Cancer
    Title:

    Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma

    Published date:
    12/03/2021
    Excerpt:
    Patients were randomized 2:1 to receive cabozantinib (60 mg orally, once daily) or a matched placebo....In the cabozantinib group, high levels of MET, HGF, IL-8, and ANG2 were associated with shorter OS in both univariate and multivariable dichotomized analyses...
    DOI:
    https://doi.org/10.1159/000519867
    Trial ID:
    CELESTIAL